Want to see TSE:ASEP full AI Analyst Report?
Top Page
ASEP Medical Holdings Inc
(ASEP)
Select Model
Select Model
Rating:31Underperform
Price Target:―
Action:N/A
Date:01/23/25
ASEP Medical Holdings Inc exhibits substantial financial difficulties, with ongoing losses and negative cash flows weighing heavily on its overall score. The technical indicators suggest a negative market sentiment, with the stock trading below key moving averages. Valuation is poor due to negative earnings and lack of dividends, emphasizing the company's current unprofitability. Without notable improvements or strategic initiatives to enhance revenue and profitability, the stock remains a high-risk investment.
Positive Factors
Low Financial Leverage
Low financial leverage suggests ASEP has a conservative capital structure, which may provide stability and reduce financial risk in the long term.
Negative Factors
Negative Cash Flow
Negative cash flow indicates ASEP struggles to generate sufficient cash from its core operations, potentially impacting its ability to fund growth and meet obligations.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Low financial leverage suggests ASEP has a conservative capital structure, which may provide stability and reduce financial risk in the long term.
Read all positive factors
ASEP Medical Holdings Inc (ASEP) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.38M
Dividend YieldN/A
Average Volume (3M)2.42K
Price to Earnings (P/E)―
Beta (1Y)-2.58
Revenue Growth13.48%
EPS Growth64.30%
CountryCA
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.36
Shares Outstanding15,873,520
10 Day Avg. Volume1,152
30 Day Avg. Volume2,423
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.24
Price to Sales (P/S)8.56
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ASEP Medical Holdings Inc Business Overview & Revenue Model
Company Description
Asep Medical Holdings Inc. is dedicated to advancing medical solutions, primarily through its subsidiary, ASEP Medical Inc. The company's core focus involves pioneering an early diagnostic method for Sepsis, as well as developing innovative peptid...
How the Company Makes Money
ASEP Medical Holdings Inc generates revenue through the development and commercialization of its proprietary medical technologies and solutions. The company earns money by licensing its innovations to pharmaceutical companies, healthcare providers...
ASEP Medical Holdings Inc Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Jun 2026 | Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 336.77K | 21.14K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -374.59K | -113.74K | -155.40K | -177.18K | -26.45K |
| EBITDA | -1.85M | -8.14M | -4.56M | -2.06M | 0.00 |
| Net Income | -4.92M | -8.23M | -5.76M | -2.30M | -28.10K |
Balance Sheet | |||||
| Total Assets | 8.72M | 25.61M | 27.08M | 30.72M | 10.98K |
| Cash, Cash Equivalents and Short-Term Investments | 153.65K | 64.72K | 2.13M | 5.29M | 8.47K |
| Total Debt | 230.00K | 20.00K | 0.00 | 0.00 | 140.71K |
| Total Liabilities | 4.38M | 3.05M | 528.16K | 144.20K | 161.51K |
| Stockholders Equity | 2.33M | 12.61M | 15.47M | 18.26M | -150.53K |
Cash Flow | |||||
| Free Cash Flow | -1.02M | -2.72M | -3.61M | -1.31M | -22.12K |
| Operating Cash Flow | -1.02M | -2.71M | -3.61M | -1.19M | -22.12K |
| Investing Cash Flow | 749.37K | -4.47K | 124.80K | 146.08K | 0.00 |
| Financing Cash Flow | 402.94K | 651.40K | 330.00K | 6.34M | 30.06K |
ASEP Medical Holdings Inc Technical Analysis
Negative
0.31
Price Trends
0.16
Negative
0.17
Negative
0.25
Negative
Market Momentum
0.02
Positive
41.38
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASEP, the sentiment is Negative. The current price of 0.31 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.16, and above the 200-day MA of 0.25, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 41.38 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ASEP.
ASEP Medical Holdings Inc Peers Comparison
UnderperformOutperform
Sector (51)
TSE:ASEP
ASEP Medical Holdings Inc
0.15
-0.35
-70.00%
TSE:DRUG
Bright Minds Biosciences
92.09
34.39
59.60%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.25
-3.76
-93.88%
ASEP Medical Holdings Inc Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Asep Medical Resumes Trading After Revocation of Cease Trade Order
Positive
Dec 16, 2025
Asep Medical Holdings Inc. announced the revocation of a Failure-to-File Cease Trade Order by the BC Securities Commission, which had been imposed due to a delay in filing annual financial statements. The revocation allows the company to resume no...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Asep Medical Holdings Updates Year-End Management Discussion and Analysis
Neutral
Dec 12, 2025
Asep Medical Holdings Inc. has amended and refiled its Management’s Discussion and Analysis for the year ended December 31, 2024. The amendments include new disclosures on the company’s intellectual properties and research and developm...
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
Asep Medical Licenses Anti-Biofilm Technology to Bondent for Oral Rinse in China
Positive
Nov 10, 2025
Asep Medical Holdings Inc. has entered into a Patent Licensing Agreement with Shanghai Bondent Technology Co., Ltd. to develop and commercialize an oral rinse using Asep’s anti-biofilm peptide technology in China and other key markets. This ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.